German optical technology leader Carl Zeiss has officially launched a specialized symposium series titled “The Future of Myopia Progression Management in Vietnam.” The programmatic roadshows completed consecutive phases in Hanoi (June 7), Da Nang (June 12), and Ho Chi Minh City (June 19), and are scheduled to continue in Can Tho (June 26) alongside a synchronized clinical training webinar (July 3). The events assemble prominent ophthalmologists and vision care experts to deploy advanced technological interventions against the rapid proliferation of pediatric myopia.
The documented pathological risks of retinal degeneration, Myo200 biometric axial parameters, and the C.A.R.E. micro-cylindrical structure of MyoEase lenses feature:
-
Asian Pediatric Myopia Demographics and Downstream Ophthalmic Pathologies:
-
Epidemiological Drivers: International datasets establish that pediatric myopia across Asian sectors is surging exponentially, driven by modernized lifestyles, extended study durations, and widespread digital screen exposure. Experts warn that myopia must not be dismissed as a simple refractive error remediated by standard eyeglasses.
-
Severe Complications: Continuous progression during childhood development directly compounds patient risks for high-acuity, vision-threatening ocular pathologies, including macular degeneration, retinal detachment, glaucoma, and early-onset cataracts. Modern clinical care dictates a multi-layered response merging lifestyle habits, outdoor exposure, and advanced optical technologies.
-
-
The Myo200 Biometric Hardware and MyoConsult Algorithmic Software Ecosystem:
-
Ocular Biometrics: Zeiss unveiled an integrated digital ecosystem engineered to optimize clinical workflows, spearheaded by the Myo200 vision care solution. The diagnostic platform executes high-precision screening to capture critical ocular biometric data, focusing specifically on Axial Length—the definitive gold standard metric used to predict future myopic acceleration.
-
Predictive Modeling: The hardware interfaces directly with MyoConsult software, a digital clinical tool powered by modern scientific algorithms that enables practitioners to visually model and map a child’s long-term diopter expansion trajectory.
-
-
C.A.R.E. Micro-Cylindrical Optical Geometries and MyoCare Clinical Registry Trials:
-
Axial Elongation Blockades: The newly introduced Zeiss MyoEase management spectacle lenses incorporate a concentric ring micro-cylindrical design designated as C.A.R.E. technology, blended with peripheral defocus management profiles. This optical architecture systematically diminishes hyperopic defocus on the peripheral retina, neutralizing the biological signaling pathways that trigger rapid axial length elongation.
-
Clinical Efficacy Data: During the sessions, Dr. Tran Dinh Minh Huy, M.D., Ph.D., alongside panel specialists, presented updated clinical trial data validating the performance, structural efficacy, and high daily wear comfort scores delivered by the flagship Zeiss MyoCare and Zeiss MyoCare S lens portfolios.
-
-
Corporate Architecture of the Carl Zeiss Group:
-
Founded in Germany in 1846, Carl Zeiss is a global technology powerhouse specializing in optics and optoelectronics, wholly owned by the Carl Zeiss Foundation. The conglomerate commands market share across four primary industrial divisions: semiconductor manufacturing technologies (lithography optics for microchips), medical technologies (ophthalmic diagnostic and microsurgical hardware), industrial quality research metrology, and consumer optics (prescription spectacle and photographic lenses).
-
Source: https://vnexpress.net/carl-zeiss-thuc-day-quan-ly-tien-trien-can-thi-bang-cong-nghe-5088567.html